XML 33 R25.htm IDEA: XBRL DOCUMENT v3.25.0.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Schedule of Diluted Net (Loss) Income Per Common Share

The Company calculates net (loss) income per common share in accordance with ASC 260, Earnings Per Share. Basic net (loss) income per common share for the years ended December 31, 2024 and 2023 was determined by dividing net (loss) income applicable to common stockholders by the weighted average number of common shares outstanding during the period. Per ASC 260, Earnings Per Share, the weighted average number of common shares outstanding utilized for determining the basic net (loss) income per common share for the years ended December 31, 2024 and 2023 includes the outstanding prefunded warrants to purchase 7,516,267 and 3,200,000 shares of common stock issued in the April 2022 Public Offering and December 2020 public offering, respectively. Diluted net (loss) income per common share for the years ended December 31, 2024 and 2023 was determined as follows (in thousands, except share and per share amounts):

 

Years Ended December 31,

 

 

2024

 

 

2023

 

Net (loss) income allocated to common shares

$

(21,288

)

 

$

67,041

 

 

 

 

 

 

Weighted average common shares outstanding – basic

 

48,513,073

 

 

 

47,852,833

 

Dilutive effect of restricted stock units

 

 

 

 

537,749

 

Weighted average common shares outstanding – diluted

 

48,513,073

 

 

 

48,390,582

 

 

 

 

 

 

Net (loss) income per share – diluted

$

(0.44

)

 

$

1.39

 

 

Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock and Outstanding Restricted Stock Units

The following potentially dilutive shares of common stock and outstanding restricted stock units that contain certain performance contingencies have not been included in the computation of diluted net (loss) income per share for the years ended December 31, 2024 and 2023, as the result would be anti-dilutive or the performance contingencies have not been met:

 

 

Years Ended December 31,

 

 

 

2024

 

 

2023

 

Outstanding stock options

 

 

2,905,029

 

 

 

1,867,795

 

Outstanding restricted stock units

 

 

3,120,374

 

 

 

400,000

 

Warrants to purchase common stock associated with December 2020 public offering - Series 2

 

 

 

 

 

6,800,000

 

Warrants to purchase common stock associated with April 2022 Public Offering

 

 

15,000,000

 

 

 

15,000,000

 

Common stock associated with the March 2019 Notes

 

 

1,138,200

 

 

 

1,138,200

 

Warrants to purchase common stock associated with Loan Agreement

 

 

198,811

 

 

 

198,811

 

Warrants to purchase common stock associated with Danforth

 

 

50,000

 

 

 

50,000

 

          Total

 

 

22,412,414

 

 

 

25,454,806